These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


58 related items for PubMed ID: 4255705

  • 1. [Animal experiment findings on intravenous use of hylase "Dessau"].
    Kretschmar KH, Weidenbach H, Bellmann H, Petter O.
    Exp Pathol (Jena); 1971; 5(3):212-6. PubMed ID: 4255705
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Pharmacodynamic effect of the combined administration of Hylase "Dessau" and Myocuran in ambulatory surgery].
    Bellmann H, Rauchfuss E, Böhland W, Scheuner G, Hutschenreiter J, Brand G, Sandner K.
    Z Arztl Fortbild (Jena); 1975 Nov 01; 69(21):1099-105. PubMed ID: 1226841
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Effect of collagenase on the permeability of the glomerular basement membrane in the rat kidney].
    Laloi C, Geloso-Meyer A, Cheignon M, Schaeverbeke J.
    C R Seances Acad Sci III; 1981 Mar 16; 292(11):721-5. PubMed ID: 6265116
    [Abstract] [Full Text] [Related]

  • 11. Studies on glomerular basement membrane. 3. Effects of steroid on membrane chemistry and its protein permeability.
    Misra RP, Berman LB.
    Lab Invest; 1972 Jun 16; 26(6):666-70. PubMed ID: 5031368
    [No Abstract] [Full Text] [Related]

  • 12. [Studies on the antigenicity problems of Hylase "Dessau"].
    Müller HD.
    Z Arztl Fortbild (Jena); 1975 Nov 01; 69(21):1105-6. PubMed ID: 1226842
    [No Abstract] [Full Text] [Related]

  • 13. [Administration of Hylase in Bechterew's disease].
    Brand G, Bellmann H, Kothe W, Duck HJ, Rauchfuss E, Fleischmann H, Schönlebe W, Böhland W.
    Z Arztl Fortbild (Jena); 1975 Nov 01; 69(21):1106-7. PubMed ID: 1226843
    [No Abstract] [Full Text] [Related]

  • 14. [Use of hylase "Dessau" in periarthritis humero-scapularis (Duplay syndrome)].
    Bellmann H, Zacharias J, Hasert V, Kretschmar KH, Weidenbach H.
    Zentralbl Chir; 1969 Sep 27; 94(39):1288-304. PubMed ID: 5371300
    [No Abstract] [Full Text] [Related]

  • 15. [Initial results of high-dosage hyaluromidase long-term therapy ("Hylase" Dessau) in dermatology].
    Wozniak KD, Braun W.
    Dtsch Gesundheitsw; 1972 Jun 01; 27(22):1046-8. PubMed ID: 4557763
    [No Abstract] [Full Text] [Related]

  • 16. [Treatment results of pelvic type arteriopathies, stadium II, with intravenous mixtures of magnesium compounds and hylase].
    Wolff L.
    Z Arztl Fortbild (Jena); 1972 May 01; 66(9):446-7. PubMed ID: 5072100
    [No Abstract] [Full Text] [Related]

  • 17. Ultrastructural analyses of control and enzyme-treated isolated renal basement membranes.
    Carlson EC, Meezan E, Brendel K, Kenney MC.
    Anat Rec; 1981 Aug 01; 200(4):421-36. PubMed ID: 6272615
    [No Abstract] [Full Text] [Related]

  • 18. Histochemistry of renal basal laminae. Adolescent compared with senescent rats.
    Rosenquist TH, Bernick S.
    J Gerontol; 1971 Apr 01; 26(2):176-85. PubMed ID: 4101836
    [No Abstract] [Full Text] [Related]

  • 19. Action of proteolytic and glycolytic enzymes on the permeability of the blood-brain barrier.
    Robert AM, Godeau G.
    Biomedicine; 1974 Jan 20; 21(1):36-9. PubMed ID: 4367421
    [No Abstract] [Full Text] [Related]

  • 20. [Therapeutic experiences with the intravenous treatment of humeral epicondylitis and tendovaginitis using Dessau's hylase].
    Schneider W, Henke R.
    Z Arztl Fortbild (Jena); 1971 Sep 15; 65(18):993-5. PubMed ID: 5151136
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 3.